SecBot SecBot
Biotech Drug Report Generated Nov 14, 2026

NVG-291

NGEN·NervGen Pharma Corp.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3 (registrational)
Time to market
If Phase 3 RESTORE succeeds, a potential FDA submission could occur in 2028-2029, assuming enrollment completes and the 16-week treatment period yields positive results. Breakthrough Therapy designation may accelerate FDA review.
Why 4/10
The next hard dated catalyst is the Phase 3 RESTORE registrational study topline data readout. Since the first patient was dosed in October 2026 and the study is a 16-week treatment period, topline data is likely 12-18+ months away, placing this in the 3-5 impact range for a single-asset company.
Actionable Insight NEUTRAL

The next major catalyst is the Phase 3 RESTORE topline data readout, likely in late 2027 or 2028 given enrollment just began in October 2026. Positive data would validate NVG-291 as a first-in-class neuroreparative therapy for a large unmet need with no approved pharmacologic alternatives; negative data would be devastating for this single-asset company. Interim enrollment updates or any early efficacy signals could also move the stock.

Price Chart

Loading chart...

Executive Summary

NVG-291 is a first-in-class therapeutic peptide from NervGen Pharma Corp. (Nasdaq: NGEN) designed to promote nerve repair in spinal cord injury by blocking the CSPG-PTPsigma pathway, a natural brake on nerve regeneration. The drug recently received FDA Breakthrough Therapy designation (November 12, 2026) based on positive Phase 1b/2a CONNECT SCI data showing functional hand use improvements in chronic spinal cord injury patients. A Phase 3 registrational study (RESTORE) began dosing its first participant in October 2026, targeting roughly 150 participants with chronic cervical motor-incomplete spinal cord injury. NervGen is a single-asset company with a market cap around $150M, raised US$60M in May 2026 to fund development, and has analyst support (7 Buy-equivalent ratings). The next major catalyst is the Phase 3 topline readout, likely 12-18+ months away.

How It Works

NVG-291 is a synthetic peptide (a short chain of amino acids) that mimics a part of a naturally occurring protein called phosphatase sigma. It works by blocking a natural "stop signal" in the body that normally prevents nerve cells from regenerating after injury to the brain or spinal cord. By blocking that stop signal, NVG-291 allows damaged nerves to repair themselves, potentially restoring function such as hand use and movement in people with chronic spinal cord injury.

Trial Status

Phase 1b/2a CONNECT SCI study (NCT05965700) completed with positive topline data from the chronic cohort. Phase 3 RESTORE registrational study began dosing first participant in October 2026, targeting ~150 participants with chronic cervical motor-incomplete spinal cord injury across US and Canada. The 16-week study uses change from baseline in GRASSP Quantitative Prehension at Week 12 as the primary endpoint.

The Two-Sided Case

▲ Bull Case6
FDA granted Breakthrough Therapy designation on November 12, 2026, based on positive Phase 1b/2a chronic cohort data, which can expedite development and expedited review.
Positive topline data from the Phase 1b/2a CONNECT SCI study showed functional hand use improvements in chronic spinal cord injury patients, with no serious adverse events or treatment discontinuations.
Successful End-of-Phase 2 meeting with FDA alignment on the Phase 3 RESTORE study design, including agreement on the primary endpoint (GRASSP Quantitative Prehension at Week 12).
NVG-291 is a first-in-class therapeutic peptide targeting the CSPG-PTPsigma pathway to promote nerve repair; no FDA-approved pharmacologic therapies exist for chronic spinal cord injury, addressing an unmet need affecting roughly 312,000 people in the US.
Analyst consensus is bullish: 6 Buy, 1 Strong Buy, 1 Hold (July 2026), with TD Cowen initiating with Buy and assuming $1.1B peak sales for NVG-291.
Institutional accumulation in Q3 2026: Marshall Wace added 41.6%, Morgan Stanley added 29%, and several advisors added or doubled positions.
▼ Bear Case5
Phase 3 RESTORE study just began dosing (October 2026); enrollment and topline data are likely 12-18+ months away, creating a long binary wait with no near-term catalyst.
The company is a single-asset developer (NVG-291 is its only pipeline drug), making the stock extremely sensitive to any negative development.
NervGen raised US$60M in a dilutive May 2026 offering priced at $2.50/share, and the stock has fallen roughly 62% year-to-date before the recent Breakthrough Therapy bounce.
A non-cash accounting restatement in September 2026, while operationally immaterial, raises governance questions.
Phase 1b/2a data came from only 24 patients; larger Phase 3 results may not replicate the functional improvements seen in the smaller study.

Upcoming Catalysts

  • Phase 3 RESTORE study enrollment updates (ongoing, no specific dates announced)
  • Phase 3 RESTORE topline data readout (likely late 2027 or 2028, 12-18+ months away)
  • Potential additional regulatory milestones under Breakthrough Therapy designation

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NervGen Pharma Corp. Press Release NGEN ·Originating report

Sources · 6

Hover a chip for the title
1 markets.businessinsider.com2 markets.businessinsider.com3 seekingalpha.com4 theglobeandmail.com5 bioworld.com6 morningstar.com